*ST春天: 青海春天股票交易异常波动公告

Core Viewpoint - The stock of Qinghai Spring Pharmaceutical Resources Technology Co., Ltd. experienced abnormal trading fluctuations in 2025, with a cumulative closing price increase of 12% over three consecutive trading days [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price increased by 12% over three consecutive trading days on August 29, September 1, and September 2, 2025, which qualifies as abnormal trading according to the Shanghai Stock Exchange rules [1][2]. - The company conducted a self-examination and confirmed with its controlling shareholder that there are no undisclosed significant matters apart from those already disclosed [1][2]. Group 2: Business Operations - The company's recent business operations and external environment have not undergone significant changes, and it does not have any undisclosed major information [1][2]. - The company confirmed that there are no major events such as asset restructuring or debt restructuring that have not been disclosed [2]. Group 3: Financial Metrics - As of September 2, 2025, the static price-to-earnings ratio of the food manufacturing industry is 29.19, while the company's static price-to-earnings ratio is -16.12, indicating a significant difference from the industry average [3]. - The company's half-year revenue for 2025 was reported at 124.87 million, with a total profit of 6.97 million [3]. Group 4: Shareholder Information - The controlling shareholder, Tibet Rong'en Technology Co., Ltd., has pledged 11.36 million shares, accounting for 60.24% of its total holdings and 19.35% of the company's total share capital [4].